xBiotech USA, Inc.

115 articles about xBiotech USA, Inc.

• XBiotech USA Announces Publication Of Clinical Results Supporting The Potential Of Its True Human(TM) Antibody As A Cardiovascular Therapy

  10/2/2015

• XBiotech USA Receives FDA Fast Track Designation For Its Novel True Human Therapeutic Antibody For Treating Serious Infections Due To Staphylococcus Aureus

  10/1/2015

• Xbiotech Advances Phase I/II Clinical Study Of Novel True Human Therapeutic Antibody For Treating Serious Infections Due To Staphylococcus Aureus

  9/1/2015

• Xbiotech Completes Enrollment For Xilonix Phase III Registration Study In Europe

  8/17/2015

• XBiotech USA Announces Expansion Of Global Phase III Registration Study In Europe Using Xilonix For Treatment Of Metastatic Colorectal Cancer

  8/7/2015

• XBiotech USA Provides Second Quarter 2015 Corporate And Clinical Update

  7/28/2015

• XBiotech USA To Provide Second Quarter Business Update

  7/15/2015

• XBiotech USA Announces Publication Of Clinical Results Supporting Its True Human Antibody Therapy For Type 2 Diabetes Mellitus

  7/7/2015

• XBiotech USA Treats First Patient In Phase I/II Clinical Study Of Novel True Human Therapeutic Antibody For Treating Serious Infections Due To Staphylococcus Aureus

  7/6/2015

• XBiotech USA Conducts Investigators Meeting To Update The Status Of Its Phase III Registration Study Underway In Europe

  7/1/2015

• XBiotech USA Announces Publication Of Phase II Clinical Results For Its True Human Antibody Mabp1 For Treating Acne Vulgaris

  6/15/2015

• XBiotech USA Appoints Kelly R. Thornburg As Senior Vice President Of Operations

  6/8/2015

• XBiotech Launching Phase I/II Clinical Study Of Novel True Human Therapeutic Antibody For Treating Serious Infections Due To Staphylococcus Aureus

  5/28/2015

• XBiotech USA Successfully Clones First Anti-Ebola Therapeutic Antibody Product Candidate

  5/27/2015

• XBiotech USA Secures Approval From Data Safety Monitoring Board To Continue Phase III Registration Study In Europe For Its Novel Cancer Immunotherapy

  5/18/2015

• XBiotech USA Enrolls First Patient Under Revised Protocol For U.S. Phase III Registration Study Using Xilonix For Treatment Of Metastatic Colorectal Cancer

  4/29/2015

• XBiotech USA Closes IPO

  4/17/2015

• XBiotech USA, Inc. Announces Pricing Of Initial Public Offering

  4/16/2015

• XBiotech USA, Inc. Announces Phase II Psoriasis Study Results in JAMA Dermatology

  3/5/2015

• Austin Biotech Firm XBiotech USA, Inc. Begins Construction On $200 Million Campus

  9/25/2014